MorphoSys (MPSYF) 6-K MorphoSys and Incyte Announce First Patient Dosed in Phase 3

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF A FOREIGN ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For May 12, 2021

Commission File Number 1-38455

MorphoSys AG

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒    Form 40-F  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐    No  ☒

If ‘‘Yes’’ is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

Exhibits
99.1	MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MORPHOSYS AG (Registrant)
Date: May 12, 2021	By:	/s/ i.V. Thomas Biegi
		Name: Thomas Biegi
		Title: Vice President; Head of Corporate Communications
	By:	/s/ i.A. Sophie Petersen
		Name: Sophie Petersen
		Title: Senior Specialist Corporate Communications